Anahita R. Dastur, Ph.D.
Affiliations: | 2007 | Cell and Molecular Biology | University of Texas at Austin, Austin, Texas, U.S.A. |
Area:
Molecular Biology, Cell BiologyGoogle:
"Anahita Dastur"Parents
Sign in to add mentor| Jon M. Huibregtse | grad student | 2007 | UT Austin | |
| (Characterization of Herc5: The major ligase for ISG15, an antiviral ubiquitin -like protein.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wang Y, Zhang L, Wei Y, et al. (2020) Pharmacological Targeting of Vacuolar H-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. Cell Chemical Biology |
| Dastur A, Choi A, Costa C, et al. (2018) NOTCH1 represses MCL-1 levels in GSI-resistant T-ALL, making them susceptible to ABT-263. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Kodack DP, Farago AF, Dastur A, et al. (2017) Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. Cell Reports. 21: 3298-3309 |
| Ham J, Costa C, Sano R, et al. (2016) Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell. 29: 159-72 |
| Dastur A, Costa C, Faber A, et al. (2016) Abstract 3846: Sensitivity of NOTCH1 mutant T-ALL to ABT-263 Cancer Research. 76: 3846-3846 |
| Faber AC, Farago AF, Costa C, et al. (2015) Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 112: E1288-96 |
| Chen L, Dastur A, Yin X, et al. (2015) Abstract A27: Transposon mutagenesis screen identifies genes conferring resistance to BRAF inhibition in melanoma Clinical Cancer Research. 21 |
| Dastur A, Faber A, Costa C, et al. (2015) Abstract A77: Repression of mTORC1 activity in NOTCH1 mutant T-ALL results in sensitivity to the BCL-2 inhibitor ABT-263 Molecular Cancer Therapeutics. 14 |
| Kwiatkowski N, Zhang T, Rahl PB, et al. (2014) Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 511: 616-20 |
| Faber AC, Coffee EM, Costa C, et al. (2014) mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discovery. 4: 42-52 |